What is Starget Pharma?
Starget Pharma operates as an early-stage clinical enterprise dedicated to the development of a novel class of Smart Targeted Radioligands. These therapeutic agents are engineered to address the complexities of hard-to-heal cancers, representing a significant advancement in precision oncology. By focusing on highly specific molecular targeting, the company aims to improve patient outcomes while minimizing systemic toxicity, a critical challenge in traditional cancer treatment modalities. The firm's strategic focus on radioligand technology places it at the intersection of diagnostic imaging and therapeutic intervention, a high-growth area within the broader biotechnology market.
How much funding has Starget Pharma raised?
Starget Pharma has raised a total of $21.5M across 2 funding rounds:
Other Financing Round
$5.1M
Stock/Share Issuance
$16.4M
Other Financing Round (2024): $5.1M with participation from The Cancer Focus Fund
Stock/Share Issuance (2026): $16.4M, investors not publicly disclosed
Key Investors in Starget Pharma
The Cancer Focus Fund
An oncology-focused investment vehicle established in collaboration with The University of Texas MD Anderson Cancer Center, specializing in precision funding for innovative cancer therapies and immunotherapies.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Starget Pharma?
With the recent influx of capital, Starget Pharma is poised to transition into more advanced clinical trial phases. The strategic roadmap likely involves scaling manufacturing capabilities for its proprietary radioligand compounds and expanding its research infrastructure to support multi-site clinical studies. As the company navigates the regulatory landscape, the focus will remain on validating the efficacy of its precision oncology platform. Investors are closely monitoring the firm's ability to translate its innovative research into viable, market-ready therapeutics, which could redefine standard-of-care protocols for difficult-to-treat malignancies in the coming years.
See full Starget Pharma company page
